INDIAN COUNCIL OF MEDICAL RESEARCH

India's ICMR and DBT-NII are developing AdFalciVax, the first indigenous recombinant chimeric malaria vaccine designed to target two critical stages of Plasmodium falciparum.

The Indian Council of Medical Research (ICMR) and Panacea Biotec have initiated India's first Phase 3 clinical trial for an indigenous tetravalent dengue vaccine called DengiAll.

Karnataka's Health and Family Welfare Department has formally requested the Drug Controller General of India to investigate alleged ethical violations in clinical trials at HealthCare Global Enterprises Ltd (HCG) in Bengaluru.

The antiviral drug Favipiravir demonstrated substantial protection against Chandipura virus in preclinical studies conducted by India's National Institute of Virology.

The Calcutta High Court remanded ITC Limited's patent application for a non-electronic nicotine aerosol delivery device after the Controller rejected it under Section 3(b) of India's Patents Act citing public health concerns.

• Indigenously developed HPV test kits for cervical cancer screening were launched in Delhi, targeting the seven to eight most common cancer-causing HPV types specific to India's population. • The RTPCR-based diagnostic kits, validated through collaborative research led by AIIMS Delhi, offer a cost-effective alternative to traditional Pap smears and HPV DNA tests for national cancer screening programs. • With cervical cancer being the second most common cancer among Indian women and accounting for 25% of global mortality, these kits align with WHO's recommendation for HPV testing as the preferred screening method.

Researchers at IIT Roorkee have discovered that efavirenz, a drug widely used for HIV treatment, significantly inhibits Chikungunya virus replication in both laboratory cell cultures and mouse models.

The Indian Council of Medical Research (ICMR) has entered into agreements to begin first-in-human clinical trials for four new drug molecules targeting various diseases.

The Indian Council of Medical Research (ICMR) has formalized partnerships with industry and academic institutions to facilitate first-in-human phase one clinical trials for four novel pharmaceutical agents.